Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04439227 · FLOW

Participant flow

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) · Source last updated 2026-10-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive adavosertib 300 mg PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Adavosertib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Ineligible
    2. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        19
      type
      Disease Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Withdrawal by Subject
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician Decision
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        33
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        33
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        30
      comment
      Primary efficacy analysis set
      type
      Eligible and Treated
    4. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        33
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Patients were assigned to this NCI-MATCH subprotocol (EAY131-Z1I) using a prospectively defined NCI-designed informatics rules algorithm (MATCHBOX). Adult patients with solid tumors carrying BRCA1/2 PVs were eligible if they had progressed on standard treatment or had no standard treatment available.
recruitment Details
Subprotocol Z1I was activated on March 13, 2017. Thirty-three patients were enrolled on EAY131-Z1I between March 24, 2017, and August 9, 2017.
Complete source fields
groups
  1. description
    Patients receive adavosertib 300 mg PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Adavosertib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Ineligible
    2. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        19
      type
      Disease Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Withdrawal by Subject
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician Decision
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        33
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        33
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        30
      comment
      Primary efficacy analysis set
      type
      Eligible and Treated
    4. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        33
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Patients were assigned to this NCI-MATCH subprotocol (EAY131-Z1I) using a prospectively defined NCI-designed informatics rules algorithm (MATCHBOX). Adult patients with solid tumors carrying BRCA1/2 PVs were eligible if they had progressed on standard treatment or had no standard treatment available.
recruitment Details
Subprotocol Z1I was activated on March 13, 2017. Thirty-three patients were enrolled on EAY131-Z1I between March 24, 2017, and August 9, 2017.

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice